Werewolf Therapeutics (HOWL) Share-based Compensation (2020 - 2026)

Werewolf Therapeutics (HOWL) has reported Share-based Compensation for 7 consecutive years, with $419000.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Share-based Compensation fell 76.63% year-over-year to $419000.0 in Q2 2026; TTM through Jun 2026 was $3.8 million, a 50.84% decrease from a year earlier, with the FY2025 full-year figure at $6.2 million, down 29.24% from the prior year.
• Share-based Compensation was $419000.0 for Q2 2026 at Werewolf Therapeutics, down from $929000.0 in the prior quarter.
• Over five years, Share-based Compensation peaked at $2.6 million in Q2 2024 and troughed at $419000.0 in Q2 2026.
• A 5-year average of $1.8 million and a median of $1.9 million in 2023 frame the typical range for Share-based Compensation.
• The widest YoY moves for Share-based Compensation: up 223.75% in 2022, down 82.12% in 2022.
• Over 5 years, Share-based Compensation stood at $1.9 million in 2022, then declined by 3.55% to $1.9 million in 2023, then rose by 1.87% to $1.9 million in 2024, then plunged by 36.43% to $1.2 million in 2025, then sank by 65.46% to $419000.0 in 2026.
• The last three Share-based Compensation figures came in at $419000.0 (Q2 2026), $929000.0 (Q1 2026), and $1.2 million (Q4 2025), per Business Quant data.